CTLA4 and melanoma: One patient with stage IV-M1d melanoma who previously progressed on anti-PD-1 and anti-CTLA-4 checkpoint blockade achieved a durable PR according to iRECIST criteria (Figure 3A, patient myDC-04 in Table A1).